Enhanced circulation effector composition and method
AssigneeAlza Corporation
InventorsSamuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz, Herve Bercovier
Life of this patent
Estimating the term…
Abstract
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
Claims48
A liposome composition, comprising
- liposomes, each having an outer layer of hydrophilic chains, and
- an effector molecule attached to the distal ends of said chains
- wherein binding of the liposomes to a first binding member or a second binding member is effective to inhibit binding between said first and second binding members.
A liposome composition for use in treating a condition mediated by binding of one binding member to a second binding member, comprising
- liposomes, each having an outer layer of hydrophilic polymer chains, and
- an effector molecule attached to the distal ends of said chains
- wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
A liposome composition for use in treating a condition mediated by binding of one binding member, which is present in the bloodstream, to a second binding member, comprising
- liposomes, each having an outer layer of hydrophilic polymer chains, and
- an effector molecule attached to the distal ends of said chains
- wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
The composition of clam 13 wherein the effector molecule is selected from the group consisting of Fab antibody fragments, cytokines, cellular growth factors, peptide hormones, monosaccharides, polysaccharides, IL-1 inhibitors, ELAM-1 binding inhibitors, and limulus antilipopolysaccharide factor (LALF).
A liposome composition for use in treating a condition mediated by binding of a first binding member, which is a pathogen or cell in the bloodstream, to a second binding member comprising
- liposomes, each having an outer layer of hydrophilic polymer chains, and
- an effector molecule attached to the distal ends of said chains
- wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
A liposome composition for use in treating a condition mediated by binding of a first binding member to a second binding member, which is a target cell, comprising
- liposomes, each having an outer layer of hydrophilic polymer chains, and
- an effector molecule attached to the distal ends of said chains
- wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
A liposome composition for use in treating a condition mediated by binding of a first binding member, which is a pathogen, to a second binding member, which is a target cell, comprising
- liposomes, each having an outer layer of hydrophilic polymer chains, and
- an effector molecule attached to the distal ends of said chains
- wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
A liposome composition for use in treating a condition mediated by binding of a first binding member, which is a cell in the bloodstream, to a second binding member, which is a target cell, comprising
- liposomes, each having an outer layer of hydrophilic polymer chains, and
- an effector molecule attached to the distal ends of said chains
- wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
A liposome composition for use in treating a condition mediated by binding of a first binding member, which is a pathogen or a cell in the bloodstream, to a second binding member, which is a target cell, comprising
- liposomes, each having an outer layer of hydrophilic polymer chains, and
- an effector molecule attached to the distal ends of said chains
- wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
Dependencies are inferred from the claim text.